In this episode of IMPACT Medicom’s podcast series on Precision Medicine in Oncology we discuss:
· The BC OncoPanel, a comprehensive genomic profiling (CGP) test available to patients with some cancers in British Columbia;
· The challenges for including CGP in laboratory budgets;
· The information exchange needed between stakeholders to accelerate access to CGP; and
· How IMPACT Medicom’s CGP prioritization report can provide decision-makers with a framework for implementing CGP testing.
Our guests:
Dr. Howard Lim is a Medical Oncologist at BC Cancer Agency and Clinical Associate Professor in the Faculty of Medicine at the University of British Columbia. He completed his medical oncology training at the BC Cancer Agency and received additional training at the Oregon Health Sciences University, specializing in gastrointestinal malignancies. Dr. Lim is actively involved in clinical trials, ethics, and genomic-based research.
Jim Slater [MLT(ART), BSc, MBA] began his career as a medical laboratory technician in BC and has since worked in all four Western provinces in the area of diagnostic services. His past leadership roles include Executive Director of all diagnostics in Saskatchewan, Chief Executive Officer of all diagnostic services in Manitoba, and most recently, Chief Provincial Diagnostics Officer at the Provincial Health Services Authority in BC. Jim currently provides Health System and Business Consulting services, with expertise in precision medicine (genomics), value-based healthcare, innovation and resource stewardship, research, and business development.
Howard and Jim both served as steering committee members on IMPACT Medicom’s CGP prioritization report. The full report can be downloaded at:
https://www.impactmedicom.com/publications/reports.
This podcast episode is sponsored by AstraZeneca Canada.
If you enjoy our podcast, please review and subscribe. For more podcasts, papers, and medical education programs, visit our website at: http://www.impactmedicom.com.